0000000000008528

AUTHOR

E. Cervera

Clinical Decision-Making when Treating Diabetic Macular Edema Patients with Dexamethasone Intravitreal Implants.

Diabetes mellitus (DM) is a metabolic disease frequently associated with comorbidities that include diabetic macular edema (DME). The current medical approach to treating DME involves intravitreal injections with either anti-vascular endothelial growth factors or steroids. However, the burden associated with intravitreal injections and DM-derived complications is high, underlining the need to find optimal treatment regimens. In this article we describe the considerations we apply when treating DME patients with dexamethasone intravitreal implants (Ozurdex®), particularly those that influence the clinical decision-making process during the follow-up period. These considerations are based bot…

research product

Beneficial Effect of Docosahexanoic Acid and Lutein on Retinal Structural, Metabolic, and Functional Abnormalities in Diabetic Rats

To assess the effect of docosahexanoic acid (DHA) and lutein (both compounds with anti-inflammatory and antioxidant properties) on experimental diabetic retinopathy.Male Wistar rats were studied: non-diabetic controls, untreated diabetic controls, and diabetic rats were treated with DHA and lutein or the combination of DHA + insulin and lutein + insulin for 12 weeks. Oxidative stress and inflammatory markers, apoptosis, and functional tests were studied to confirm biochemical and functional changes in the retina of diabetic rats. Malondialdehyde (MDA), glutathione concentrations (GSH), and glutathione peroxidase activity (GPx) were measured as oxidative stress markers. TUNEL assay and caspa…

research product

Desprendimiento del vítreo posterior y vitreolisis farmacológica: la nueva era de la vitrectomía enzimática

research product

Vitrectomía enzimática por inyección intravítrea de plasmina autóloga como tratamiento inicial del edema macular diabético difuso

espanolObjetivo: Determinar si la inyeccion intravitrea de plasmina es efectiva en el tratamiento del edema macular diabetico difuso (EMDD). Diseno: Estudio piloto prospectivo, comparativo, de intervencion, serie de casos. Pacientes: Dieciocho pacientes con edema macular diabetico bilateral, recibieron como primera actuacion terapeutica una inyeccion intravitrea de plasmina en un ojo, sirviendo el ojo contralateral como control. Tratamiento: Inyeccion intravitrea de 0,2 ml de plasmina autologa bajo anestesia topica. La plasmina fue obtenida por un metodo simplificado. Principales medidas: Engrosamiento macular central (EMC) medido por tomografia de coherencia optica (OCT) y agudeza visual (…

research product

Capsulorrexis asistida mediante azul brillante (BBG) para cirujanos en formación

research product

Intravitreal pegaptanib sodium for refractory pseudophakic macular oedema.

Evaluate the efficacy of intravitreal pegaptanib sodium (Macugen®) in refractory pseudophakic cystoid macular oedema (CME). Prospective, nonrandomized, interventional case series. Four eyes of four patients with refractory pseudophakic CME to pars plana vitrectomy and intravitreal bevacizumab and triamcinolone, were treated with pegaptanib sodium, with a mean follow up of 4 months. Pre- and postinfection examinations included assessment of best-corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study chart (ETDRS), fluorescein angiography (FA), and optical coherence tomography (OCT). Visual acuity increased in all patients after intravitreal pegaptanib sodium. OCT…

research product

Altas dosis de azul brillante G intravítreo

research product

Plasmina autóloga para inyección intravítrea sin vitrectomía asociada: método simplificado de preparación con streptokinasa

research product

Topical cyclosporine as an alternative treatment for herpetic interstitial keratitis

research product